Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
44
CYTK Quote, Financials, Valuation and Earnings
Last price:
$64.27
Seasonality move
:
6.31%
Day range:
$63.20 - $65.28
52-week range:
$29.31 - $70.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
87.58x
P/B ratio:
61.87x
Volume:
1.1M
Avg. volume:
2.1M
1-year change:
32.25%
Market cap:
$7.8B
Revenue:
$18.5M
EPS (TTM):
-$6.31
Analysts' Opinion
-
Consensus RatingCytokinetics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $85.44, Cytokinetics, Inc. has an estimated upside of 33.13% from its current price of $64.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $41.00 representing 36.12% downside risk from its current price of $64.18.
Fair Value
-
According to the consensus of 13 analysts, Cytokinetics, Inc. has 33.13% upside to fair value with a price target of $85.44 per share.
CYTK vs. S&P 500
-
Over the past 5 trading days, Cytokinetics, Inc. has overperformed the S&P 500 by 5.78% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cytokinetics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cytokinetics, Inc. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Cytokinetics, Inc. reported revenues of $1.9M.
Earnings Growth
-
Cytokinetics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cytokinetics, Inc. reported earnings per share of -$2.55.
Enterprise value:
8.1B
EV / Invested capital:
11.95x
Price / LTM sales:
87.58x
EV / EBIT:
--
EV / Revenue:
92.63x
PEG ratio (5yr expected):
-0.60x
EV / Free cash flow:
-17.82x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$77.6M
Return On Assets:
-55.59%
Net Income Margin (TTM):
-862.21%
Return On Equity:
--
Return On Invested Capital:
-120.55%
Operating Margin:
-8613.38%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $7.8M | $3.2M | $87.2M | $463K | $1.9M | |
| Gross Profit | -$2.4M | -$10.3M | $77.6M | -$1.9M | -$743K | |
| Operating Income | -$495.8M | -$524.6M | -$572.9M | -$140.8M | -$166.8M | |
| EBITDA | -$485.6M | -$511.1M | -$563.3M | -$138.4M | -$164.1M | |
| Diluted EPS | -$5.52 | -$5.39 | -$6.31 | -$1.36 | -$2.55 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $494.9M | $884.3M | $561.4M | $1B | $977.3M | |
| Total Assets | $827.5M | $1.1B | $740.6M | $1.4B | $1.4B | |
| Current Liabilities | $80.9M | $76.5M | $77.7M | $109.8M | $142.1M | |
| Total Liabilities | $578.5M | $1.1B | $1.2B | $1.4B | $2B | |
| Total Equity | $249M | -$16M | -$438.8M | -$13.9M | -$521.1M | |
| Total Debt | $239.8M | $725.2M | $731.2M | $770.8M | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$438.5M | -$404.4M | -$432.9M | -$101.5M | -$107.5M | |
| Cash From Investing | $349.9M | -$745.4M | $198.7M | -$45.1M | -$71M | |
| Cash From Financing | $82.4M | $1.1B | $416.1M | $3.4M | $330.5M | |
| Free Cash Flow | -$443M | -$407.1M | -$453.4M | -$102.2M | -$116.9M | |
CYTK
Sector
Market Cap
$7.8B
$28.1M
Price % of 52-Week High
90.42%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-1.63%
-1.49%
1-Year Price Total Return
32.25%
-17.13%
Beta (5-Year)
0.584
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$62.75
200-day SMA
Buy
Level
$45.69
Bollinger Bands (100)
Buy
Level
44.58 - 65.2
Chaikin Money Flow
Buy
Level
6M
20-day SMA
Buy
Level
$63.74
Relative Strength Index (RSI14)
Buy
Level
52.50
ADX Line
Buy
Level
17.99
Williams %R
Neutral
Level
-58.5702
50-day SMA
Buy
Level
$62.80
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
23.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.9825)
Sell
CA Score
(Annual)
Level (-6.0031)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (5.0778)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, CYTK has received 10 Buy ratings 3 Hold ratings, and 0 Sell ratings. The CYTK average analyst price target in the past 3 months is $85.44.
-
Where Will Cytokinetics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cytokinetics, Inc. share price will rise to $85.44 per share over the next 12 months.
-
What Do Analysts Say About Cytokinetics, Inc.?
Analysts are divided on their view about Cytokinetics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cytokinetics, Inc. is a Sell and believe this share price will drop from its current level to $41.00.
-
What Is Cytokinetics, Inc.'s Price Target?
The price target for Cytokinetics, Inc. over the next 1-year time period is forecast to be $85.44 according to 13 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is CYTK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cytokinetics, Inc. is a Buy. 10 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CYTK?
You can purchase shares of Cytokinetics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cytokinetics, Inc. shares.
-
What Is The Cytokinetics, Inc. Share Price Today?
Cytokinetics, Inc. was last trading at $64.27 per share. This represents the most recent stock quote for Cytokinetics, Inc.. Yesterday, Cytokinetics, Inc. closed at $64.18 per share.
-
How To Buy Cytokinetics, Inc. Stock Online?
In order to purchase Cytokinetics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CYTK Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CYTK
Sector
P/E ratio
--
23.89x
PEG ratio
-0.60x
-0.01x
P/B ratio
61.87x
1.81x
Price / LTM sales
87.58x
1.59x
Growth Metrics
CYTK
Sector
Revenue growth
318.14%
4.62%
Earnings growth
-87.06%
11.06%
Revenue (5-year growth)
-7.22%
6.5%
Earnings forecast
-$1.57
-$0.21
Profitability
CYTK
Sector
Profitability FY 2024
$8.9M
$3.6M
Return on invested capital
-120.55%
-31.84%
Return on assets
-55.59%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
CYTK
Sector
Total cash
$965.6M
$26.4M
Short term investments
$981.2M
$25.7M
Total assets
$1.4B
$76.9M
Long term debt
$1.2B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
